Abstract
Patients were recruited from the dialysis unit at City Hospital, Nottingham and a satellite unit at King's Mill Centre, Mansfield, UK. All patients with end-stage chronic renal mone replacement therapy (HRT ). Dietary calcium intake failure who had been on haemodialysis for longer than 1 was <500 mg/day in all but two patients, whose intake was month and who were able to complete an interview were 500-1000 mg/day. considered eligible. Of the 106 patients who gave their consent, four died, two received renal transplants and one moved to another city before completing the study. Five Data collection patients withdrew their consent for the DXA scan due to concern about exposure to radiation, and four failed to Collection of demographic data and treatment details was attend for the DXA scan. One DXA scan failed due to performed by means of a structured interview and review of technical problems. Eighty eight patients completed the study patient folders and treatment records. Current physical activand their demographic data and biochemistry are summar-ity levels were assessed using a questionnaire developed by ized in Table 1 . There were 48 males (54.5%) and 40 females Sallis et al. [14] and are expressed in metabolic equivalents (45.5%), of whom 32 were post-menopausal or permanently (METs). Dietary calcium intake was documented with a amenorrhoeic. The racial composition of the group was: nine questionnaire developed and validated by the Dietetics Asian (10.2%), seven black (8.0%) and 72 white (81.8%). Department at City Hospital. Weight is measured before and Chronic renal failure was of unknown aetiology in 34 patients after dialysis in all patients. The weight used in this study (38.6%) and due to glomerulonephritis in 14 (15.9%), adult was the average of three post-dialysis weights recorded in polycystic kidney disease in eight (9.1%), diabetic nephro-the week prior to entry. pathy in seven (8.0%), hypertension in six (6.8%), obstructive uropathy in five (5.7%), reflux nephropathy in four (4.5%), renovascular disease in three (3.4%), amyloidosis in three Biochemistry (3.4%) and non-recovery of acute renal failure in three (3.4%). The mean duration of dialysis in the group was 41.5 Serum urea, creatinine, albumin, calcium, phosphate and alkaline phosphatase are measured every 2 months using months (range 1-266 months) and the hours of dialysis per week ranged from 7-15 with a mean of 11.2. The dialysate standard autoanalyser techniques. Calcium levels were corrected for albumin concentration. The urea reduction ratio calcium concentration was 1.0 mmol/l in 24 patients, 1.25 mmol/l in three patients and 1.5 mmol/l in 61 patients. ( URR) was calculated using urea levels before and after dialysis. Intact PTH levels were measured within 6 months Six patients (6.8%) had suffered fractures of long bones (excluding phalanges) since commencement of renal replace-of entry into the study using a radioimmunoassay ('Incstar' Atlantic Antibodies). From 24 January 1997, this was ment therapy, and seven (8.0%) had undergone partial parathyroidectomy for severe secondary hyperparathyroid-changed to a chemiluminescent enzyme immunometric assay performed with an automated analyser ('Immulite', ism. Gastric acid suppression therapy (either H 2 receptor antagonists or proton pump inhibitors) was being taken by Diagnostic Products Corp.). Results from the latter assay were converted to make them comparable with the results 32 patients (36.4%), and 12 (13.6%) were taking warfarin. None of the post-menopausal females were receiving hor-from the previous assay using a formula developed and validated by the Clinical Chemistry Laboratory at City a stepwise linear multiple regression analysis. These Hospital. included all the factors listed in Table 1 and, in addition, gender, history of long bone fracture, current smoking, previous parathyroidectomy, cumulative Bone densitometry duration of previous transplant function, treatment DXA studies of the lumbar spine and left hip (or right hip with gastric acid suppression therapy and treatment if this was not possible for technical reasons) were performed with warfarin. The analysis was repeated for femoral by the Radiology Department at City Hospital using a neck BMD and total hip BMD. Independent variables 'Lunar Expert-XL' densitometer (Lunar Corp.). Both sys-which entered the equation for different analyses and tems report actual values obtained and T-and Z-scores reached statistical significance (P-values <0.05) are which reflect the number of standard deviations by which a shown in Table 3 . To examine associations within patient's value differs from the mean of a group of young subgroups, the process was repeated using the data for normal or age-matched controls, respectively. Thus a T-score female patients and for patients over 60 years. In the of −2.5 represents a BMD value 2.5 standard deviations former analysis, age at menarche and menopausal below the mean of a young normal population. The WHO status were added as independent variables; results are has defined osteoporosis in terms of T-score criteria.
Osteopaenia is defined as a T-score of between −1.0 and shown in Table 4 was only moderately reduced, a significant proportion of patients were at increased risk for fractures. Little is known about the fracture risk of haemodialysis
Results
patients with reduced BMD. In the only comprehensive epidemiological study reported by Gupta and colBone densitometry leagues, hip fracture risk among US Medicare endstage renal failure patients was increased 3-to 4-fold The results of bone densitometry measurements in the [3] . In the general population, the risk of fracture 88 patients who completed the study are shown in increases 1.5-3 times for each standard deviation of Table 2 . A high degree of correlation was found decrease in BMD [13] . Six of our patients had a history between DXA measurements at the two different sites of long-bone fracture, and there was a negative associin the femur (r=0.92; P<0.001); correlation coeffiation between a history of fracture since the commencecients between DXA lumbar spine values and femoral ment of renal replacement therapy and femoral neck neck (r=0.53; P<0.001) or total hip (r=0.60; BMD in patients over 60 years, confirming that the P<0.001), though lower, were still statistically risk is increased. significant.
The relatively weak correlation between lumbar and femoral DXA measurements (r=0.60 and 0.53) is Factors associated with reduced bone mineral density probably related to the effects of spinal osteophytes and aortic calcification which may spuriously elevate Possible risk factors for and biochemical markers of bone disease were entered as independent variables in lumbar BMD measurements [18]. aT-score ∏−2.5; bT-score <−1.0 but >−2.5. 
aGastric acid suppression therapy; bage at menarche; coral calcium supplementation; dparathyroidectomy; efracture since commencing renal replacement; fweekly heparin dose (units).
Cortical porosity is increased in hyperparathyroid-parathyroidism. This is supported by a similar finding in another cross-sectional study [16 ] and by longitudism [19] and it is therefore not surprising that serum PTH is an important determinant of BMD. As can be inal studies following parathyroidectomy [24] .
Adynamic bone disease and osteomalacia may both seen from Tables 3 and 4 , serum PTH was negatively associated with BMD measurements. Secondary hyper-be associated with reduced BMD but, as this study did not include bone histology, we are unable to comment parathyroidism remains the most common type of renal bone disease found in haemodialysis patients. on the prevalence in this population. Aluminium overload may be responsible for both conditions, and the Either in isolation or as part of a mixed renal osteodystrophy picture, it has been reported on bone biopsy in definitive diagnosis of this rests with the discovery of aluminium deposits at the mineralization front on bone 57 of 117 (49%) haemodialysis patients [7] and in 61 of 73 (84%) in a mixed group of haemo-and peritoneal histology. In both our units, dialysate water aluminium content is measured routinely 6 monthly and is consistdialysis patients [17] . Several studies have reported a similar negative association between PTH levels using ently below the recommended standard of 10 mg/l.
Serum aluminium levels are measured routinely in only a variety of measurements of BMD [20] [21] [22] . Other studies, however, have been unable to show a negative a small number of patients prescribed aluminium hydroxide as a phosphate binder, and this parameter association between PTH levels and BMD [8] [9] [10] [11] 23] . While this may be explained by the small number of was therefore not included in the multi-variant analysis.
Age and weight have emerged as important deterpatients or the use of C-terminal PTH assays in some of the studies, it suggests that other factors affect BMD minants of BMD in our study. Age-related bone loss plays an important role in the pathogenesis of osteoin haemodialysis patients. In female patients, previous parathyroidectomy was positively associated with fem-porosis and has been shown to occur in normal adults at a rate of 1-2% per year after age 40 years, increasing oral BMD ( Table 4) , suggesting recovery of the skeleton after correction of secondary hyper-to 2-4% for 5-8 years following menopause in women [1] . Several studies in dialysis patients have reported a for 5-8 years, and this contributes to the higher prevalence of osteoporosis in women than in men [1] . negative association between age and BMD in female but not in male patients with end-stage renal disease Peak bone mass has also been shown to be reduced in women with later menarche [30] . Many studies of [20, 25] . Two studies found no association between age and BMD [11, 21] . However, the mean age of patients BMD in dialysis patients have not examined the effect of gender and one has found no difference between in these studies was 43 and 50.5 years, respectively, while in our study patients were older with a mean age the rate of bone loss in men and women [15] . However, Foldes et al. using tibial ultrasound reported reduced of 58.2 years. As dialysis programmes are accepting more and more elderly patients who are also experien-BMD in female patients [21] , and Luisetto et al. found lower femoral and lumbar spine BMD in females [31] . cing markedly improved survival rates, age-related bone loss can be expected to become an increasingly One study found that total and pelvic BMD were lower in females over 50 years compared with those important factor affecting bone disease in these patients. In the normal population, there is a positive under 50 [20] , and another reported a lower femoral neck BMD in women with secondary amenorrhoea correlation between weight and BMD [26 ] . This has been attributed to stimulation of bone formation by [16 ] . There is evidence both from animal and human studies that oestrogen deficiency increases the sensitivweight bearing and to increased peripheral conversion of adrenal androgens to oestrogens by adipose tissue. ity of bone to PTH [32] . These findings have important practical implications as oestrogen deficiency following We have shown a similar association in our patients; though most studies in haemodialysis patients have menopause can be corrected with HRT. None of the patients in this study was receiving HRT. not assessed patient weight, two studies have reported a positive association between body mass index and
The relationship between calcium intake, vitamin D supplementation and osteoporosis remains controvermeasures of BMD [16, 21] .
The finding of a negative association between gastric sial. A review of 37 studies showed that calcium supplements had a consistent effect in preventing bone acid suppression therapy and BMD was unexpected and, to our knowledge, has not been reported previ-loss in 12 interventional studies in post-menopausal women and that the effect was greatest in studies ously. However, a case-control study of risk factors for hip fracture in men found an increased risk of in which the baseline calcium intake was low [33] .
Few studies have addressed the issue of calcium fracture (odds ratio=1.8) in those who had been treated previously with cimetidine, an effect attributed supplementation in haemodialysis patients, although oral 1a-hydroxycalciferol treatment has been shown to to its hormonal side effects (blocking of androgen receptors and inhibition of oestradiol 2-hydroxylation) prevent the loss of BMD at the lumbar spine in 165 male patients [34] . Many of our patients were receiving [27]. Hormonal effects would, however, not explain the association in our patients as the majority were calcium-containing phosphate binders and we found a positive association between calcium supplementation receiving omeprazole and not cimetidine. Although gastric acid previously was thought to be necessary to and both measures of femoral BMD in patients over 60 years ( Table 4 ). There was no association with mobilize insoluble calcium complexes in food, calcium absorption has been shown to be normal after inhibi-dietary calcium intake but this was probably due to the fact that 86 of 88 patients were taking in <500 mg tion of gastric acid secretion by cimetidine [28] . An alternative explanation is suggested by animal experi-of calcium per day in their diets. We were unable to demonstrate any association between 1a-hydroxycalciments which have shown that the hypergastrinaemia resulting from omeprazole therapy is associated with ferol therapy and BMD.
The positive association between weekly heparin hypertrophy of the parathyroid glands and a decrease in femoral BMD [29] . There was, however, no differ-dose, femoral neck BMD in the whole group and total hip BMD in patients over 60 years was unexpected as ence in PTH levels between our patients receiving gastric acid suppression therapy and those not receiv-high dose heparin therapy has been associated with a decrease in BMD [35] . However, the dose of heparin ing it (mean 250 ng/l vs 232 ng/l; P=0.7). These findings require confirmation and further investigation, in our patients (mean=14 727 U/week) was much lower than the >10 000 U/day in these reports. There as dyspepsia and peptic ulcer disease are common in haemodialysis patients and many receive gastric acid was a positive correlation between heparin dose and patient weight (r=0.39; P<0.001), and this probably suppression therapy (36% in our study).
Our results suggest that hormonal factors also affect explains the above observations. We were surprised that the cumulative dose of bone density in haemodialysis patients. Female sex was negatively associated with total hip BMD in the group corticosteroids did not enter the regression equation in any of the analyses, as osteoporosis is a well as a whole and in the subgroup of patients over 60 years. In female patients, there was a negative associ-documented complication of long-term steroid therapy.
However, there is evidence to suggest that steroidation with age at menarche. We were unable to show any effect of menopause or amenorrhoea, but this may induced osteoporosis is reversible, at least in young patients [36 ] . As the use of steroids in our patients have been due to the fact that 32 of the 40 female patients (80%) fell into this category. Hormonal factors was mostly historical (as part of the immunosuppression for previous renal transplants), this may explain are major determinants of BMD in patients without renal failure. Following menopause, bone loss increases the lack of association. 
